Search | Clinical Trials Finder

Conditions: Cognitive Impairment, Cognitive Decline, Cognition Disorders in Old Age, Well-Being, Psychological, Inflammation, Cognitive Fun
Interventions: LasoperinTM, Placeo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Sleep Insufficiency
Interventions: Personalized Trial ABCCBA, Personalized Trial CBAABC; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Care
Interventions: Skin Imaging, Facial Cleanser; Device · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Breast Inflammatory Carcinoma, Locally Recurrent Breast Carcinoma
Interventions: Exercise Intervention, Educational Intervention, Supportive Care, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Accelerometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing; Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Major Bleeding
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Chandler, Arizona • Orange, California • Sacramento, California + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Multiple Myeloma
Interventions: RO6870810, daratumumab; Drug · Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Duarte, California • Stanford, California • Jacksonville, Florida + 5 more

Conditions: Asthma
Interventions: Fluticasone Propionate; Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Schizophrenia
Interventions: PEAR-004, Sham; Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Garden Grove, California • Oakland, California • Torrance, California + 3 more

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Uniplas, Cryosupernatant plasma; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Centreville, Virginia

Conditions: Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)
Interventions: Care4Today® Connect CAD-PAD Mobile Application; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Aurora, Colorado • Jacksonville, Florida • Overland Park, Kansas + 2 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 16 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more

Conditions: Hematopoietic and Stem Cell Transplant
Interventions: General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years), General Health Module-Baseline Parent Report-Adolescent (13-18 years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), General Health Module-Follow Up Parent Report-School Age (5-12 years), Demographic Data Form, SCT Daily Activity Log, The Functional Independence Measure for Children, Manual Muscle Testing, 3-Minute Step Test, HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years), HSCT Module-Follow Up Parent Report-adolescent (13-18 years), HSCT Module-Follow Up Parent Report-School Age (5-12 years); Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 7 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chin Retrusion
Interventions: JUVÉDERM VOLUMA® XC; Device
Lead sponsor: Allergan; Industry
Eligibility: 22 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: San Diego, California • Coral Gables, Florida • Miami Beach, Florida + 11 more

Conditions: Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Interventions: Harmony TPV System; Device
Lead sponsor: Medtronic Heart Valves; Industry
Eligibility: Not listed
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 6 more

Conditions: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Interventions: mRNA-2416, Durvalumab; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 5 more

Conditions: Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
Interventions: Pedometer-based Walking Program; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Residual Neuromuscular Blockade, Curarization, Postoperative Residual, Postoperative Respiratory Complication
Interventions: Observational Study; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101,510 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: Advanced Solid Tumors
Interventions: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix, Hematologic Malignacies
Interventions: GeneTherapy; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Infection
Interventions: Delve Detect CSF mNGS Test, Real-World Data; Diagnostic Test · Other
Lead sponsor: Delve Bio, Inc.; Industry
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Head and Neck Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, docetaxel, fluorouracil, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: PF-05280014, Paclitaxel, Herceptin®; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Plainville, Connecticut • Southington, Connecticut • Boca Raton, Florida + 1 more

Search by objective public record fields.

A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults

A Personalized Mind-Body Intervention (MBI) for Improving Sleep Among Women Working in Healthcare

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

12-Week Study in Adult Subjects With Asthma

Study of Efficacy of PEAR-004 in Schizophrenia

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Deconditioning in Transplant

A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

Validation of the REPS Prediction Tool

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)